Resnik E, Trujillo Y P, Taxy J B
Department of Obstetrics and Gynecology, Cancer Care Center, Lutheran General Hospital, Park Ridge, Illinois, USA.
J Surg Oncol. 1997 Apr;64(4):299-303. doi: 10.1002/(sici)1096-9098(199704)64:4<299::aid-jso9>3.0.co;2-4.
The relationship of the tumor DNA content to survival of patients with advanced epithelial cancer has not yet been clarified. A large amount of contradictory data exists in the literature. This study analyzes the putative relationship between ploidy and advanced ovarian carcinoma.
A retrospective analysis of tumor ploidy, DNA index, and the S-phase fraction from 35 patients with nonborderline epithelial ovarian carcinomas was determined by flow cytometry of paraffin-embedded tissue. All patients had FIGO stage III or IV disease. Those patients who survived > 5 years were assigned to Group A (10 patients). Group B consisted of 25 age-matched subjects who succumbed to their disease within 5 years of diagnosis.
Group A had not reached a median overall survival with a median follow-up of 114 months (range 67-226), whereas Group B had a median overall survival of 17 months (range 1-48). Two of the patients in Group A and all of the patients in group B had died of the disease. The two groups were similar in age, histologic type, and treatment. In Group A, three patients had grade 1 tumors, in contrast to group B where all the patients had either grade 2 or 3 disease (P = 0.018). However, the distribution of aneuploidy was similar in both groups. Also, the DNA indices were similar: 1.40 +/- 0.42 in Group A, and 1.36 +/- 0.44 in Group B. The median S-phase fraction was 14% (range 3-23%) in Group A, and 15% (range 2-23%) in Group B. The grade and type of tumor were not related to the ploidy or the DNA index. There was no significant correlation between ploidy or the DNA index and survival.
This study suggests that the DNA content of tumor as measured by flow cytometry is not a predictor of long-term survival in ovarian cancer patients with advanced disease.
晚期上皮癌患者的肿瘤DNA含量与生存之间的关系尚未阐明。文献中存在大量相互矛盾的数据。本研究分析倍性与晚期卵巢癌之间的假定关系。
对35例非交界性上皮性卵巢癌患者的肿瘤倍性、DNA指数和S期分数进行回顾性分析，通过石蜡包埋组织的流式细胞术确定。所有患者均为国际妇产科联盟（FIGO）Ⅲ期或Ⅳ期疾病。存活超过5年的患者被分配到A组（10例患者）。B组由25例年龄匹配的患者组成，这些患者在诊断后5年内死于该疾病。
A组在中位随访114个月（范围67 - 226个月）时未达到中位总生存期，而B组的中位总生存期为17个月（范围1 - 48个月）。A组有2例患者和B组所有患者均死于该疾病。两组在年龄、组织学类型和治疗方面相似。A组有3例患者为1级肿瘤，而B组所有患者均为2级或3级疾病（P = 0.018）。然而，两组非整倍体的分布相似。此外，DNA指数也相似：A组为1.40±0.42，B组为1.36±0.44。A组的中位S期分数为14%（范围3% - 23%），B组为15%（范围2% - 23%）。肿瘤的分级和类型与倍性或DNA指数无关。倍性或DNA指数与生存之间无显著相关性。
本研究表明，通过流式细胞术测量的肿瘤DNA含量不是晚期卵巢癌患者长期生存的预测指标。
